Clinical Trials for Lung Cancer

201409100

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein Phase III Principal Investigator Govindan, Ramaswamy…

201605133

Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC Phase III Principal Investigator Robinson, Clifford Disease Site Lung Learn more about this study at: clinicaltrials.gov

201704098

Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial Phase II/III Principal Investigator Robinson, Clifford Disease Site…

201711149

A virtual clinical trial to assess the impact of Dual-Energy CT on plan quality, dose-delivery accuracy, and simulated outcomes of patients treated with proton or photon therapy Phase N/A Principal Investigator Robinson, Clifford Disease Site…

201802012

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects with Advanced Non-Small Cell Lung Cancer Phase I Principal Investigator Govindan, Ramaswamy Disease Site Lung Learn…

201803113

A Phase 1/2 Study of Relatlimab (anti-LAG-3 Monoclonal Antibody) Administered in Combination with Both Nivolumab (anti-PD-1 Monoclonal Antibody) and BMS- 986205 (IDO1 inhibitor) or in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in…

201807049

A Phase 1 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 757 in Subjects with Small Cell Lung Cancer Phase I (Cancer Control) Principal Investigator Govindan, Ramaswamy Disease Site Lung Learn more about this…

201807070

A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With…

201808082

A Phase I/II Multi-site Study of Rucaparib and Pembrolizumab Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer after Initial Therapy with Carboplatin, Pemetrexed, and Pembrolizumab Phase I/II Principal Investigator Morgensztern, Daniel Disease Site…

201809104

Phase 1 Study of SC-011 as a Single-Agent and in Combination with an Immunoregulatory Molecule in Subjects with Relapsed or Refractory Small Cell Lung Cancer (SCLC) Phase I (Cancer Control) Principal Investigator Morgensztern, Daniel Disease…

201901190

A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001) Phase I/II Principal Investigator Waqar, Saiama Disease…

201902012

A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Stage I/II Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) Phase III (Cancer Control) Principal…

201904154

A Phase 2, Open-Label Study of Encorafenib + Binimetinib in Patients with BRAFV600E-mutant Non-small Cell Lung Cancer Phase II (Cancer Control) Principal Investigator Morgensztern, Daniel Disease Site Lung Learn more about this study at: clinicaltrials.gov

201905001

A Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors Phase II Principal Investigator Waqar, Saiama Disease Site Corpus Uteri; Ill-Defined Sites; Lip, Oral Cavity and Pharynx; Liver; Lung;…

201905035

A Single-Arm Phase II Study with a Safety Lead-in of Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy with Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung…

201906081

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) Phase I/II Principal Investigator Park,…

201908024

A Pilot Study of Daily Imaging, Target Identification, and Simulated Computed Tomography-Based Stereotactic Adaptive Radiotherapy Workflow in a Novel Ring Gantry Radiotherapy Device Phase N/A Principal Investigator Henke, Lauren Disease Site Anus; Bones and Joints;…

201909014

NRG-LU005, Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/II Randomized Study of Chemoradiation versus Chemoradiation plus atezolizumab Phase III Principal Investigator Robinson, Clifford Disease Site Lung Learn more about this study at: clinicaltrials.gov

201909026

A Phase 1b/2a Pilot Randomized Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T-Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or in Combination with Pembrolizumab in HLA-A2+ Participants with NY-ESO-1-…

201910170

A Phase 1b, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects with Advanced Solid Tumors With KRAS p.G12C Mutation Phase I Principal Investigator Govindan, Ramaswamy Disease Site Breast; Esophagus;…

201911138

A Phase 1b Efficacy and Safety Study of Cofetuzumab Pelidotin (ABBV-647, a PTK7-Targeting Antibody Drug Conjugate) in Subjects with PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer Phase I (Cancer Control) Principal Investigator Morgensztern, Daniel Disease Site…

201911207

REPLATINUM: A Phase 3, Controlled, Open-label, Randomized Study of RRx-001 Administered Sequentially with a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Lung Cancer Phase III (Cancer Control) Principal Investigator Morgensztern,…

201912015

A Phase 1/2a Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN536 in Patients with Advanced Cancers Associated with Mesothelin Expression Who Have Failed Standard Available Therapy Phase…

201912097

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-4830 as Monotherapy and in Combination with Pembrolizumab for Participants with Advanced Solid Tumors Phase I Principal Investigator Adkins, Douglas Disease Site Kidney; Larynx; Lip, Oral…

202001160

A Phase 1, Multicenter, Open-label, Dose-Exploration and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 650 in Subjects With Advanced Solid Tumors Phase I (Cancer Control) Principal Investigator Govindan, Ramaswamy Disease Site…

202002010

Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Alectinib, Entrectinib, or Vemurafenib Plus Cobimetinib in Patients with Stages I-III Non-Small Cell Lung Cancer with ALK, ROS1, NTRK, or BRAF V600E Molecular Alterations Phase II Principal…

202002050

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase…

202003096

A Phase 1/2 Trial of MRTX849 in Combination with TNO155 in Patients with Advanced Solid Tumors with KRAS G12C Mutation Phase I/II (Cancer Control) Principal Investigator Park, Haeseong Disease Site Colon; Corpus Uteri; Lung; Ovary;…

202003167

MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK) Phase III Principal Investigator Robinson, Clifford Disease Site Lung Learn more about this…

202003168

A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib vs Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III…

202003170

Master Protocol to Assess the Safety and Recommended Phase 2 Dose of Next Generations of Autologous Enhanced NY-ESO-1/ LAGE-1a TCR Engineered T-cells, alone or in combination with other agents, in Participants with Advanced Tumors Phase…

202004247

A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE SAFETY AND PRELIMINARY EFFICACY OF NKTR-214 IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS Phase I/II (Cancer Control) Principal Investigator Govindan,…

202005122

First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors Phase I/II Principal Investigator Ward, Jeffrey Disease Site Breast; Cervix; Corpus Uteri; Ill-Defined Sites; Lip, Oral Cavity…

202005130

A Phase 2, Randomized, Multicenter, Double-blind, Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line, Metastatic KEAP1/NRF2-mutated Non-Squamous, Non-Small Cell Lung Cancer (NSCLC) Phase II (Cancer…

202007030

Integration of immunotherapy into adjuvant therapy for resected NSCLC: ALCHEMIST chemo-IO Phase III Principal Investigator Govindan, Ramaswamy Disease Site Lung Learn more about this study at: clinicaltrials.gov

202008047

An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ- 73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants…

202008068

A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Phase III Principal Investigator Waqar,…

202008087

Phase 2, Multicenter, Randomized Study of DS-1062a in Advanced or Metastatic Non-Small Cell Lung Cancer with Actionable Genomic Alterations and Previously Treated with Kinase Inhibitor Therapy and Platinum-based Chemotherapy with or without Prior Immunotherapy Phase…

202009003

A phase IB and randomized open-label phase II study of M6620 in combination with carboplatin/gemcitabine/avelumab in patients with chemotherapy-naïve advanced non-small cell lung cancer of squamous cell histology Phase I/II Principal Investigator Morgensztern, Daniel Disease…

202009216

A Firstin-human Phase I, non-randomized, open-label, multicenter dose escalation trial of BI 764532 administered by repeated intravenous infusions in patients with Small Cell Lung Carcinoma and other neuroendocrine neoplasms expressing DLL3 Phase I Principal Investigator…

202011085

OLDER NON-SMALL CELL LUNG CANCER PATIENTS (>/= 70 YEARS OF AGE) TREATED WITH FIRST-LINE MK-3475 (PEMBROLIZUMAB) +/- CHEMOTHERAPY (ONCOLOGISTS/PATIENTS CHOICE) Phase II Principal Investigator Morgensztern, Daniel Disease Site Lung Learn more about this study at:…

202012066

A PHASE Ib /II STUDY OF APG-115 IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMAS OR ADVANCED SOLID TUMORS Phase I/II Principal Investigator Van Tine, Brian Disease Site Brain and Nervous System;…

202104110

A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC Phase II Principal Investigator Morgensztern, Daniel Disease Site Lung; Lung Cancer – Non-small Cell…

202104122

A Pilot Study to Evaluate the Safety and Efficacy of Zimberelimab (AB122) in Combination with Domvanalimab (AB154) and Etrumadenant (AB928) in Patients with Previously Treated Non-Small Cell Lung Cancer Phase II Principal Investigator Morgensztern, Daniel…